CDK6 and myelofibrosis: investigated the efficacy of CDK4 and CDK6 inhibitor palbociclib alone or in integrating with ruxolitinib in Jak2V617F and MPLW515L murine models of myelofibrosis, and their findings indicate that CDK6 inhibitor palbociclib in integrating with ruxolitinib effectively ameliorates myelofibrosis.23